WO2019158749A1 - Méthode, dispositif et kit de détection précoce du cancer du sein - Google Patents

Méthode, dispositif et kit de détection précoce du cancer du sein Download PDF

Info

Publication number
WO2019158749A1
WO2019158749A1 PCT/EP2019/053960 EP2019053960W WO2019158749A1 WO 2019158749 A1 WO2019158749 A1 WO 2019158749A1 EP 2019053960 W EP2019053960 W EP 2019053960W WO 2019158749 A1 WO2019158749 A1 WO 2019158749A1
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
markers
ngal
egfr
ohdg
Prior art date
Application number
PCT/EP2019/053960
Other languages
English (en)
Inventor
Márquez Márquez LIDIA
Original Assignee
Lidia Marquez Marquez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lidia Marquez Marquez filed Critical Lidia Marquez Marquez
Priority to JP2020543797A priority Critical patent/JP2021514064A/ja
Priority to US16/970,151 priority patent/US20210104323A1/en
Priority to AU2019220452A priority patent/AU2019220452A1/en
Priority to CA3090606A priority patent/CA3090606A1/fr
Priority to CN201980012961.5A priority patent/CN111712713A/zh
Publication of WO2019158749A1 publication Critical patent/WO2019158749A1/fr

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
    • G06F17/10—Complex mathematical operations
    • G06F17/18—Complex mathematical operations for evaluating statistical data, e.g. average values, frequency distributions, probability functions, regression analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Definitions

  • This invention refers to a method and device for the early detection of breast cancer and involves an analysis of a plurality of blood markers.
  • Prior art Breast cancer is a malignant proliferation of epithelial cells that line the mammary ducts and lobules. It is a clonal disease wherein an individual cell that is the product of a series of somatic or germline mutations acquires the capacity to divide itself without control or order, making it reproduce until it forms a tumour. This tumour, which starts as a slight anomaly, invades neighbouring tissue and finally spreads to other parts of the body. Therefore, an efficient and early diagnosis is necessary to prevent this possibility.
  • Infiltrating ductal carcinoma which starts in the ducts that carry milk from the breast to the nipple is, by far, the most common - approximately 80% of cases-.
  • In second place comes infiltrating lobular carcinoma - approximately 10% of cases which starts in the part of the breast called lobules, which produce breast milk.
  • the remaining types of breast cancer do not exceed 10% of cases.
  • the main risk factors for contracting breast cancer include advanced age, first menstruation at a very early age, a first pregnancy at an advanced age or never having given birth, and family background. In between 5% to 10% of cases, breast cancer is caused by inherited genetic mutations.
  • breast cancer diagnosis can only be determined by means of a breast biopsy.
  • breast cancer diagnosis methods by means of a blood analysis that detects antibodies compatible with the development of breast cancer. These concern non-invasive tests -blood analysis- in which the serum is separated from the blood and, once separated, the antibodies found are analysed as described in documents EP2446272, W09858978 and W02008032084.
  • Another example described in the prior art is document US2015/0024960 which refers to early breast cancer diagnosis. More specifically, it refers to a group of biomarkers configured to diagnose the appearance of breast cancer in blood containing an antibody that recognises it specifically. Notwithstanding, according to scientific consensus in this field, an efficient marker does not exist, nor does any predictive method contemplate its use.
  • NGAL Neurotrophil Gelatinase-Associated Lipocalin
  • the selection criteria for these patients were: (a) having been diagnosed with operable breast cancer; (b) not having previously suffered another tumour; (c) that the disease is not in an advanced or metastatic phase; (d) had not previously received neoadjuvant cancer treatment; and (e) accepts being included in the study.
  • the control group it is characterised as healthy women whose selection criteria were that they were not suffering chronic pathologies, or had any history of cancer. They also had to accept, logically, being included in the study.
  • the EGFR was significantly higher in the controls, as indicated in previous prior art publications.
  • the 8-OHDG marker was significantly higher in the cases, this being the first time this marker has been studied in early breast cancer diagnosis.
  • a mathematical equation made up of five markers was obtained, i.e. CA 15.3, NSE, NGAL, EGFR and 8-OHDG which achieve a correct breast cancer diagnosis probability of 91.8%.
  • the object of this invention is a method, a device and a kit for the early diagnosis of breast cancer which, starting from the scientific findings of the experimentation undertaken in the document [Bayo J, Castano MA, Rivera F, Navarro F. Analysis of blood markers for early breast cancer diagnosis. Clin Transl Oncol. 2017 Aug 14], improve the efficiency of the diagnosis and increase its simplicity.
  • Another object of this invention is to increase the success rate of classic breast cancer diagnosis markers. As indicated in the prior art, no markers exist that, until now, have been shown to be effective in this clinical situation. Notwithstanding, this invention shows that the relationship between the experimental markers 8-OHDG/EGFR is effective in the early diagnosis of breast cancer. This object is reached with the method of claim 1. In dependent claims, the use of additional markers that increase the effectiveness of the invention method is described.
  • the invention method, the device this method uses and the diagnostic kit helps support different clinical cases by means of the inclusion of a calculation algorithm which, through a simple blood extraction, enables a plurality of tumour markers, the presence or absence of the disease, to be determined with a success rate higher than 90%.
  • the method, device and kit described in this invention can be used in large high-risk groups of the population of different ages to supplement or replace mammograms, being a non-invasive method, does not induce iatrogenic radiations and, therefore, can be repeated as often as necessary, and, furthermore, is suitable for all ages.
  • FIG.1 shows a ROC curve of a first example of the practical embodiment of the invention.
  • FIG.2 shows a second ROC curve of a second example of the practical embodiment of the invention.
  • FIG.3 shows a third ROC curve of a third example of the practical embodiment of the invention.
  • the CEA, CYFRA, NSE and NGAL markers were higher in the patients (p ⁇ 0.05) although their behaviour in isolation showed scant diagnostic sensitivity. Furthermore, factors such as age, menopause, job, BMI and low levels of vitamin D proved to be risk variables for the disease. Logistic regression analysis of the ratio evaluated yielded a performance in isolation of 82.4% (see example 1 ) which rose to 91.2% (see example 2) by combining said quotient with other markers, obtaining a multivariate predictive equation that includes NSE and NGAL, which can improve to up to 92.8% owing to the synergistic interaction of different markers (see example 3).
  • Example 1 Clinical interest of the 8-OHDG/EGFR ratio. Bivariate analysis. The tables below show the results of the analyses of the trial results for early breast cancer diagnosis. Figure 1 shows the ROC curve of the trial.
  • Sample 1 (Cases)
  • Sample 2 (Controls) Size of the sample 62 62
  • Example 2 Clinical interest of the 8-OHDG/EGFR ratio. Multivariate analysis.
  • FIG. 2 shows the ROC curve of the trial.
  • the predictive value improves to 91.2% in a non-iterative model, with the use of the 80HDG/EGFR ratio and the NSE and NGAL markers, in the early detection of breast cancer at a significantly lower cost than the method proposed in the document [Bayo J, Castaho MA, Rivera F, Navarro F. Analysis of blood markers for early breast cancer diagnosis. Clin Transl Oncol. 2017 Aug. 14]as it uses one marker (CA 15.3) less than the aforementioned analysis.
  • B is the estimated parameter
  • ET is the typical error
  • GL are the degrees of freedom
  • SIGMA is the standard deviation. The three parameters with the lowest standard deviations will be taken into account (80HDG/EGFR, NSE and NGAL ratio).
  • Example 3 Clinical interest of the 8-OHDG/EGFR ratio. Multivariate analysis.
  • Figure 3 shows the ROC curve of the trial.
  • the predictive value improves to 92.8% in a non-iterative model, with the use of the 80HDG/EGFR ratio and the NSE, NGAL and NGAL * CA15.3 markers, in the early detection of breast cancer with greater diagnostic precision.
  • B is the estimated parameter
  • ET is the typical error
  • GL are the degrees of freedom
  • SIGMA is the standard deviation.
  • the parameters they are RATIO (i.e. the relationship between 80HDG/EGFR), NSE (marker NSE), RATIONGAL (i.e. the product between RATIO, which is the relationship between the markers 80HDG/EGFR, and the marker NGAL), CYFRANSE (i.e. the relationship between the markers CYFRA and NSE) and NGALCA153 (i.e. the relationship between the markers NGAL and CA 15.3).
  • RATIO i.e. the relationship between 80HDG/EGFR
  • NSE marker NSE
  • RATIONGAL i.e. the product between RATIO, which is the relationship between the markers 80HDG/EGFR, and the marker NGAL
  • CYFRANSE i.e. the relationship between the markers CYFRA and NSE
  • NGALCA153 i.e. the relationship between the markers
  • a device comprising means configured to execute the invention method or can be distributed by means of a kit comprising the markers indicated in any of the embodiments (examples 1 to 3) and means to execute the method described which, logically, comprises means to undertake blood or urine analysis as well as means to calculate the probability of breast cancer affectation according to the examples described and which can be easily implemented, for example, in an IT system with sufficient calculation capacity.
  • This IT system in a non-limiting way, can be anything from an application executable on a computer, tablet or mobile phone to a dedicated electronic device, the only required condition being that it implements the formulae indicated in each one of the examples, by means of instructions executable by a processor.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Data Mining & Analysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Computational Mathematics (AREA)
  • Mathematical Analysis (AREA)
  • Public Health (AREA)
  • Mathematical Physics (AREA)
  • Pure & Applied Mathematics (AREA)
  • Databases & Information Systems (AREA)
  • Mathematical Optimization (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)

Abstract

L'invention concerne une méthode de détection précoce du cancer du sein comprenant : (a) la détection de marqueurs 8-OHDG et EFGR dans le sang ou l'urine ; et (b) le calcul statistique de la probabilité d'une affectation par le cancer du sein à l'aide des données résultant de la détection des marqueurs de l'étape (a) et est caractérisé en ce que le calcul de la probabilité d'une affectation par le cancer du sein comprend l'utilisation d'une combinaison des marqueurs 8-OHDG, EGFR, NSE, CA 15-3 et NGAL.
PCT/EP2019/053960 2018-02-18 2019-02-18 Méthode, dispositif et kit de détection précoce du cancer du sein WO2019158749A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2020543797A JP2021514064A (ja) 2018-02-18 2019-02-18 乳癌の早期発見のための方法、装置、およびキット
US16/970,151 US20210104323A1 (en) 2018-02-18 2019-02-18 Method, device and kit for the early detection of breast cancer
AU2019220452A AU2019220452A1 (en) 2018-02-18 2019-02-18 Method, device and kit for the early detection of breast cancer
CA3090606A CA3090606A1 (fr) 2018-02-18 2019-02-18 Methode, dispositif et kit de detection precoce du cancer du sein
CN201980012961.5A CN111712713A (zh) 2018-02-18 2019-02-18 用于乳腺癌的早期检测的方法、装置和试剂盒

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382094.3 2018-02-18
EP18382094.3A EP3527989B1 (fr) 2018-02-18 2018-02-18 Procédé, dispositif et kit pour la détection précoce du cancer du sein

Publications (1)

Publication Number Publication Date
WO2019158749A1 true WO2019158749A1 (fr) 2019-08-22

Family

ID=61952612

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/053960 WO2019158749A1 (fr) 2018-02-18 2019-02-18 Méthode, dispositif et kit de détection précoce du cancer du sein

Country Status (8)

Country Link
US (1) US20210104323A1 (fr)
EP (1) EP3527989B1 (fr)
JP (1) JP2021514064A (fr)
CN (1) CN111712713A (fr)
AU (1) AU2019220452A1 (fr)
CA (1) CA3090606A1 (fr)
ES (1) ES2876038T3 (fr)
WO (1) WO2019158749A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117173083A (zh) * 2022-07-22 2023-12-05 浙江省肿瘤医院 基于舌象图像和肿瘤标志物的肿瘤预测系统、方法及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998058978A1 (fr) 1997-06-24 1998-12-30 Exxon Chemical Patents, Inc. Copolymere sequence polyolefinique agissant en tant qu'agent de modification de la viscosite
WO2008032084A1 (fr) 2006-09-13 2008-03-20 Oncimmune Ltd Procédés de dosage immunologique
EP2446272A2 (fr) 2009-06-23 2012-05-02 Eventus Diagnostics Israel Ltd. Procédé et système de détection du cancer
US20150024960A1 (en) 2012-03-08 2015-01-22 Snu R&Db Foundation Multiple biomarker set for breast cancer diagnosis, method of detecting the same, and diagnosis kit for breast cancer using antibody against the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007217861A1 (en) * 2006-02-17 2007-08-30 Children's Medical Center Corporation Free NGAL as a biomarker for cancer
KR20130017527A (ko) * 2011-08-11 2013-02-20 주식회사 젠닥스 대장암, 갑상선암, 유방암 또는 신장암의 진단 방법
JP6656233B2 (ja) * 2014-09-10 2020-03-04 アイディーシージーエス クリニカ デ ジアギノースチコス メディコス リミターダ 乳癌を評価するためのバイオマーカー
EP3221452A4 (fr) * 2014-11-21 2018-11-21 Caris Science, Inc. Sondes oligonucléotidiques et leurs utilisations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998058978A1 (fr) 1997-06-24 1998-12-30 Exxon Chemical Patents, Inc. Copolymere sequence polyolefinique agissant en tant qu'agent de modification de la viscosite
WO2008032084A1 (fr) 2006-09-13 2008-03-20 Oncimmune Ltd Procédés de dosage immunologique
EP2446272A2 (fr) 2009-06-23 2012-05-02 Eventus Diagnostics Israel Ltd. Procédé et système de détection du cancer
US20150024960A1 (en) 2012-03-08 2015-01-22 Snu R&Db Foundation Multiple biomarker set for breast cancer diagnosis, method of detecting the same, and diagnosis kit for breast cancer using antibody against the same

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BAYO J ET AL: "Analysis of blood markers for early breast cancer diagnosis", CLINICAL AND TRANSLATIONAL ONCOLOGY, SPRINGER ITALIA SRL, ITALY, SPAIN, vol. 20, no. 4, 14 August 2017 (2017-08-14), pages 467 - 475, XP036464965, ISSN: 1699-048X, [retrieved on 20170814], DOI: 10.1007/S12094-017-1731-1 *
BAYO J; CASTAHO MA; RIVERA F; NAVARRO F: "Analysis of blood markers for early breast cancer diagnosis", CLIN TRANSL ONCOL., 14 August 2017 (2017-08-14)
BAYO J; CASTANO MA; RIVERA F; NAVARRO F: "Analysis of blood markers for early breast cancer diagnosis", CLIN TRANSL ONCOL, 14 August 2017 (2017-08-14)
BAYO J; CASTANO MA; RIVERA F; NAVARRO F: "Analysis of blood markers for early breast cancer diagnosis", CLIN TRANSL ONCOL., 14 August 2017 (2017-08-14)
HARRIS L; FRITSCHE H; MENNEL R: "American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer", J CLIN ONCOL, vol. 25, 2007, pages 5287 - 312, XP055419000, DOI: doi:10.1200/JCO.2007.14.2364
KHATCHERESSIAN J.L; HURLEY P; BANTUG E ET AL.: "Breast Cancer Follow-Up and Management After PrimaryTreatment: American Society of Clinical Oncology Clinical Practice Guideline Update", J CLIN ONCOL, vol. 30, 2012
PEETER KARIHTALA ET AL: "Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 11, no. 1, 21 June 2011 (2011-06-21), pages 262, XP021102374, ISSN: 1471-2407, DOI: 10.1186/1471-2407-11-262 *
STURGEON C.M; DUFFY M.J; STENMAM U-H ET AL.: "National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers", CLINICAL CHEMISTRY, vol. 54, no. 12, December 2008 (2008-12-01)

Also Published As

Publication number Publication date
JP2021514064A (ja) 2021-06-03
EP3527989B1 (fr) 2020-11-25
CN111712713A (zh) 2020-09-25
US20210104323A1 (en) 2021-04-08
AU2019220452A1 (en) 2020-09-03
CA3090606A1 (fr) 2019-08-22
EP3527989A1 (fr) 2019-08-21
ES2876038T3 (es) 2021-11-11

Similar Documents

Publication Publication Date Title
Visvanathan et al. Monitoring of serum DNA methylation as an early independent marker of response and survival in metastatic breast cancer: TBCRC 005 prospective biomarker study
Chan et al. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass
Hiltermann et al. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor
Nossov et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?
Ihata et al. Amino acid profile index for early detection of endometrial cancer: verification as a novel diagnostic marker
Di Gioia et al. Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC)
Henry Biomarkers in veterinary cancer screening: applications, limitations and expectations
Plebani et al. HE4 in gynecological cancers: report of a European investigators and experts meeting
Stiekema et al. A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer
Tuomi et al. Risk-stratification of endometrial carcinomas revisited: a combined preoperative and intraoperative scoring system for a reliable prediction of an advanced disease
Yin et al. The levels of Ki-67 positive are positively associated with lymph node metastasis in invasive ductal breast cancer
Ploussard et al. The role of prostate cancer antigen 3 (PCA3) in prostate cancer detection
Zhao et al. Different levels of CEA, CA153 and CA125 in milk and benign and malignant nipple discharge
Lehtinen et al. REG4 is highly expressed in mucinous ovarian cancer: a potential novel serum biomarker
Yorozuya et al. Evaluation of Onco type DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer
Bahrami-Ahmadi et al. Symptomatic metastasis prediction with serial measurements of CA 15.3 in primary breast cancer patients
Engerud et al. Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer
US20210104323A1 (en) Method, device and kit for the early detection of breast cancer
Lokich et al. Assessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic mass
An et al. Muscle-related parameters as determinants of survival in patients with stage I-III gastric cancer undergoing gastrectomy
Mannelli et al. Nomograms predictive for oncological outcomes in malignant parotid tumours: recurrence and mortality rates of 228 patients from a single institution
Yi et al. Wnt7a deficiency could predict worse disease-free and overall survival in estrogen receptor-positive breast cancer
Chang et al. Time-dependent squamous cell carcinoma antigen in prediction of relapse and death of patients with cervical cancer
Mellouli et al. Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract
Shin et al. Novel predictive models of early death less than 1 year in patients with metastatic renal cell carcinoma after treatment with first-line tyrosine kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19708411

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3090606

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020543797

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019220452

Country of ref document: AU

Date of ref document: 20190218

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 19708411

Country of ref document: EP

Kind code of ref document: A1